DexTech Medical says OsteoDex stabilized disease in all myeloma study patients
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Baiyin Nonferrous Group Reports Q3 Net Profit of 636.9 Million Yuan
M impact | EQUITY | Oct 29, 2026, 12:51 PM UTC
Zensar Technologies Shares Jump 8.17%, Rise 25% in a Month
Zensar Technologies shares rose nearly 8.17% Thursday, extending their gains to around 25% over the past month.
M impact | EQUITY | Oct 29, 2026, 12:51 PM UTC
BioMarin Licenses Fabry Disease Therapy From GC Biopharma and Hanmi Pharm
BioMarin entered an exclusive license for a Fabry disease therapy from GC Biopharma and Hanmi Pharm.
M impact | EQUITY | Oct 29, 2026, 12:50 PM UTC
National Medical Care Reports Q3 Net Profit of SAR 87.024 Million
M impact | EQUITY | Oct 29, 2026, 12:50 PM UTC
Silicom Reports Q3 Revenue of $26.7 Million, Adjusted EPS of $0.04
M impact | EQUITY | Oct 29, 2026, 12:50 PM UTC
Al Baha reports Q3 net profit of SAR 2.66855 million
M impact | EQUITY | Oct 29, 2026, 12:49 PM UTC